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Human Papillomavirus (HPV) vaccines have been considered potentially cost-eﬀective for the reduction of cervical cancer burden
in developing countries; their eﬀectiveness in a public health setting continues to be researched. We conducted an HPV prevalence
survey among Colombian women with invasive cancer. Paraﬃn-embedded biopsies were obtained from one high-risk and one
low-middle-risk regions. GP5+/GP6+ L1 primers, RLB assays, and E7 type speciﬁc PCR were used for HPV-DNA detection.
217 cases were analyzed with 97.7% HPV detection rate. HPV-16/18 prevalence was 63.1%; HPV-18 had lower occurrence in
the high-risk population (13.8% versus 9.6%) allowing for the participation of less common HPV types; HPV-45 was present
mainly in women under 50 and age-speciﬁc HPV type prevalence revealed signiﬁcant diﬀerences. Multiple high-risk infections
appeared in 16.6% of cases and represent a chance of replacement. Age-speciﬁc HPV prevalence and multiple high-risk infections
might inﬂuence vaccine impact. Both factors highlight the role of HPVs other than 16/18, which should be considered in cost-
eﬀectiveness analyses for potential vaccine impact.
Copyright © 2009 Ra´ ul Murillo et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Cervical cancer continues to be the major cause of cancer
mortality among women in developing countries [1]. Virtu-
ally all cases of cervical cancer are attributable to persistent
Human Papillomavirus (HPV) infections, leading to the
conclusion that HPV infection is a necessary cause of the
disease [2].
T h en e wH P Vv a c c i n e sa r ed e s i g n e dt op r e v e n tH P V
16 and 18 infections which are the cause of about 70%
of invasive cervical cancer cases worldwide. Thus, they are
considered to be one of the most cost-eﬀective interventions
for cervical cancer control, particularly in developing coun-
trieswherecytology-basedscreeningprogramshavenotbeen
successful [3].
HPV vaccine eﬃcacy is 93%–100% for reducing CIN/2-
3 lesions associated with HPV 16 and 18 types [4, 5];
consequently, it has been estimated that they can reduce
the burden of cervical cancer up to 70% worldwide [6].
Furthermore, several studies reveal that no major variation
exists in speciﬁc HPV type prevalence among invasive cervi-
cal cancer in diﬀerent regions around the world, indicating
that the impact of HPV vaccines on cervical cancer incidence
and mortality is expected to be similar across continents,
with a potential reduction of 65% in South/Central America
[6].
Although various cost-eﬀectiveness analyses, including
Latin American countries, have been conducted based on
available HPV prevalence information, there are some
concerns about the inclusion of HPV vaccines in public
health programs. The factor with the greatest inﬂuence on
HPV 16/18 vaccine cost-eﬀectiveness is price per vaccinated
girl [7]; another inﬂuential factor is vaccine eﬀectiveness,
and data from Latin America show that reduction of cervical
cancer incidence could range widely (55%–69%) depending
on HPV 16/18 prevalence [8].2 Infectious Diseases in Obstetrics and Gynecology
Duetoethicalrestrictions,theburdenofcancerrelatedto
speciﬁc HPV types should be estimated based on prevalence
surveys. The most important surveys have been summarized
in global meta-analyses providing relevant information for
designing HPV vaccines as well as for assessing their impact
inallregionsoftheworld.Somelimitationsonmeta-analysis
and original studies are the diﬀerences in PCR technologies
usedtodetermineHPVinfectionandtheanalysisofmultiple
infections [9].
The abovementioned factors are crucial when consid-
ering second generation vaccines with broader coverage of
HPVtypesandthepotentialbeneﬁtsofcross-protectionwith
current vaccines [9, 10]. In light of this, there is a need
to more precisely examine the prevalence of diﬀerent HPV
types in Latin America, in order to more successfully predict
potential cost-eﬀectiveness of the introduction of current
and future HPV vaccines. The aim of our study was to
determine the prevalence of diﬀerent HPV types in cervical
cancer (squamous cell carcinoma and adenocaricnoma) in
two Colombian cities with diﬀerent risks for cervical cancer
(incidence and mortality).
2. Methods
The study protocol was approved by the Ethics Committee
of the National Cancer Institute of Colombia and each
participating institution provided further approval.
2.1. Case Selection. The cases were retrieved from 18 clinical
centers in two Colombian cities categorized as high risk
(Barranquilla) and low-middle risk (Bogota) according to
incidence and mortality from cervical cancer [11, 12].
The biggest clinical centers representing diﬀerent sectors
within the Colombian health system were invited to partic-
ipate in both cities (private medical care, health insurance
companies, and public hospitals). Formalin-ﬁxed paraﬃn-
embedded biopsies were provided in sequential order by
pathologists from each institution, corresponding to all
available invasive cervical cancer histological diagnosis for
2006-2007.
Clinical records were reviewed and patients with a
history of HIV or any other immunodeﬁciency condition
were excluded as well as patients who had undergone
chemotherapy or radiotherapy prior to specimen collection.
Tissues from paraﬃn blocks were processed at the
National Cancer Institute of Colombia and all cases were
reviewed by an expert pathologist who veriﬁed histopatho-
logical diagnosis, assigned diagnostic groups, and graded
according to standard histological criteria [13].
2.2. DNA Extraction. After histopathological review, ten
5–10/μm sections of formalin-ﬁxed paraﬃnembedded tis-
sue were sliced from each block and placed in sterile
1.5mLEpendorftubeswith1mLoctane.Thesectionswere
obtained after deep cutting into the block at least twice, and
microtome blade and histotechnician gloves were changed
for each case.
Paraﬃn was removed with consecutive rounds of octane
extraction followed by 100% ethanol washes. After high-
speed centrifugation of the tissues, samples were added with
10μL acetone and the tubes dried at 55◦C. The samples
were incubated in digestion buﬀer (100μL of 200μg/mL
Proteinase K) for 3 hours at 55◦C and 12 additional hours at
37◦C. Gentle centrifugation was carried out and the enzyme
inactivated for 10 minutes at 95◦C. 10μL of the sample were
used for PCR analysis after additional gentle centrifugation.
To assess the quality of the target DNA, all samples were
prescreened using a 209-base-pair amplifying β-globin PCR
with BPCO3 and BPCO5 primer combination [14]. If a
specimen was initially β-globin negative, new sections were
obtained from the paraﬃn block and the whole process was
repeated once.
2.3. HPV Detection. HPV-DNA detection was performed by
a standard GP5+/GP6+ PCR based assay, which allows for
the detection of a broad spectrum of genital HPV types [14].
Subsequently, HPV-positive samples were subjected to EIA-
HPV group-speciﬁc analysis using cocktail probes for high-
risk and low-risk HPV [15]. The high-risk HPV cocktail
contained oligoprobes for HPV 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 66, and 68 and the low-risk HPV contained
oligoprobes for HPV 6, 11, 26, 34, 40, 42, 43, 44, 53, 54,
55, 57, 61, 70, 71, 72, 73, 81, 82, 83, 84, IS39, and CP6108
[16].
2.4. HPV Type Speciﬁc Detection. Detection of 37 individual
HPV types was achieved using a Reverse Line Blot assay
(RLB), with a previously described system [16]. Brieﬂy,
in this method 37 oligonucleotide probes containing a
5 -amino group were covalently attached to a membrane
in parallel lines using a miniblotter. After binding of the
oligos, the membrane was removed from the miniblotter.
For hybridization, 10μL of the PCR products were added
to 150μL 2X SSPE/0.1% SDS, and the PCR products were
denatured for 10 minutes at 99◦C and cooled in ice. The
membrane (with the oligonucleotide probes) was incubated
for 5 minutes at room temperature in 2X SSPE/0.1% SDS
and placed in a miniblotter, in a way that the slots were per-
pendiculartothelinepatternoftheappliedoligonucleotides.
The slots were ﬁlled with the diluted PCR products (160μL)
and hybridized for 60 minutes at appropriate temperature.
The samples were removed by aspiration and the membrane
was washed twice in 2X SSPE/0.5% SDS for 10 minutes at
51◦C.
Subsequently the membrane was incubated with 1 :
4000 diluted peroxidase labelled streptavidin conjugate in
2X SSPE/0.5% SDS (Roche, Mannheim, Germany) for 1
hour and washed in 2X SSPE/0.5%. For chemilumines-
cent detection of hybridized DNA, the membrane was
incubated for 2 minutes in 20mL of ECL detection liq-
uid (Amersham, Buckinghamshire, England) and exposed
to a ﬁlm (Hyperﬁlm; Amersham, Buckinghamshire, Eng-
land) for 30 minutes. Films were then developed. For
repeated use, the membranes were stripped and stored at
4◦C.Infectious Diseases in Obstetrics and Gynecology 3
Table 1: Main variables in study population.
Characteristics Bogota Barranquilla All cases
(n = 123) (n = 94) (n = 217)
Average age (SD) 50.9 (14) 52.3 (13.9) 51.5(14)
Histologic type
Squamous cell carcinoma (SCC) 107 (87%) 78 (83%) 185 (86%)
Adenocarcinoma (ACC) 12 (10%) 11(12%) 23 (11 %)
Unspeciﬁed 4 (3%) 5 (5%) 8 (4%)
Distribution of SCC
Keratinizing (Well-diﬀerentiated) 31 (29%) 10 (13%) 41 (22%)
Non-keratinizing 76 (71%) 68 (87%) 144 (78%)
Distribution of ACC
Endocervical 12 (100%) 10 (91%) 22 (96%)
Endometrioid 0 (0%) 1 (9%) 1 (4%)
Histologic classiﬁcation based on 14.
2.5. HPV E7 Type-Speciﬁc PCR. HPV E7 type-speciﬁc PCR
for14high-riskHPVtypes(HR-HPV)wasusedtoanalyzeβ-
globinpositiveandHPVnegativecaseswiththeGP5+/GP6+
PCR-EIA. PCR primers and conditions were described
previously [2, 17]. PCR product detection was performed
under the same abovementioned conditions.
2.6. Statistics. Based on available data on incidence and
number of cases for the two regions included in the study
[11], independent sample size for each city was estimated
and corrected for ﬁnite populations. A 5% precision and
57%/12.5% prevalence for 16/18 types, respectively [17],
resulted in a sample size of 108 cases in Barranquilla and 140
in Bogota.
As described by S¨ arndalletal.[18],prevalenceaspropor-
tion of cases and the corresponding 95%CI were determined
for each city (independent universes) as well as for the
total number of cases. High-risk HPV (HR-HPV), low-risk
HPV (LR-HPV) [19], and speciﬁc HPV type prevalence were
determined for single and multiple infections. For additional
estimates (histological types, cumulative prevalence, age-
speciﬁc prevalence, impact of vaccination), high-risk mul-
tiple infections were assigned in proportional fractions to
each genotype according to the distribution of their single
infections.
The diﬀerences among continuous variables were ana-
lyzed with the Student’s t-test and the Wilcoxon rank-
sum test. The distribution of noncontinuous variables was
analyzed with the chi-square test and Fisher’s exact test.
3. Results
After reviewing inclusion criteria, biological specimens from
268 cases were collected in both cities. 20 cases were
excluded (8 carcinoma in situ or less, 7 inadequate biological
specimens, and 5 with no tumor or tissue from adjacent
organs other than cervix uteri). 26 (10.5%) out of 248 cases
were β-globin negative and DNA-HPV was not found in
5 cases (2%), leaving 217 cases for ﬁnal analysis (94 from
Barranquilla, 123 from Bogota).
The overall mean age was 51.5, with no signiﬁcant
variation between squamous cell carcinoma (53.2) and
adenocarcinoma (51.3). Squamous cell carcinoma (SCC)
corresponded to 86% and adenocarcinoma (ACC) to 11% of
cases, with no signiﬁcant diﬀerences between cities (Table 1).
Table 2 describes 24 HPV types identiﬁed in our study
either in single or in multiple infections: 15 HR-HPV, 4 LR-
HPV, 3 probable HR-HPV, and 2 undetermined risk types
[19]. In the high-risk city (Barranquilla) 1.1% of cases were
foundwithnoHR-HPVtypescorrespondingto0.3%overall;
for these cases single infections with low-risk types were
identiﬁed (HPV-44 and other unspeciﬁed LR-HPV).
HPV-16 was the most common type (50.4% and 52.1%
in Bogota and Barranquilla, resp.), followed by HPV-18
(13.8%and9.6%),HPV-45(9.7%and6.4%),HPV-31(7.3%
and 4.2%), and HPV-58 (6.5% and 4.2%). For the low-
middle-risk city (Bogota) the ﬁrst 5 abovementioned HPV
types were observed in 87.7% of cases, while in the high-
risk city these types corresponded to only 65.9% of cases
(P = .04),allowingforahigherparticipationoflesscommon
HPV types.
HPV types found in SCC had a similar distribution to
other published results from around the globe since most of
the cases corresponded to the SCC histologic category (over
80% in Table 1). The 5 most prevalent HPV types accounted
for 82.3% of SCC; in contrast, only 3 HPV types (16, 18,
and 31) accounted for 94.6% of ACC cases (Table 3). HPV
types18and31weremoreprevalentamongACC(32.9%and
14.9%)thantheywereinSCC(10.8%and4.5)(P>. 05),and
HPV-44 (the unique speciﬁc LR-HPV identiﬁed in a single
infection) was observed only in SCC.
Out of the total number of cases, 16.6% had multiple
infections. Simultaneous occurrence of HPV types was
present in 5% of HPV-16-associated cases, 47% of HPV-
18, 14% of HPV-45, 23% of HPV-31, and 5% of HPV-
58 (Figure 1). The majority of HPV-18 multiple infections
werethecombinationwithHPV-26(Table 2).Afterassigning
high-risk multiple infections in proportional fractions to
each genotype according to the distribution of their single
infections, 63.2% of cases were attributed to HPVs 16/18
(Figure 1).4 Infectious Diseases in Obstetrics and Gynecology
Table 2: Types of Human Papillomavirus in the study.
(a) HPV type-speciﬁc prevalence
HPV type Bogota Barranquilla
Single All 95%CI Single All 95%CI
High risk
Any HR-HPV 81.3 100.0 — 85.1 98.9 97.2–100
HPV-16 48.8 50.4 42.2–58.6 45.7 52.1 43.6–60.6
HPV-18 4.9 13.8 8.1–19.5 7.4 9.6 4.5–14.6
HPV-45 7.3 9.7 4.9–14.6 6.4 6.4 2.2–10.5
HPV-31 5.7 7.3 3.0–11.6 3.2 4.2 0.8–7.7
HPV-58 5.7 6.5 2.4–10.6 3.2 4.2 0.8–7.7
HPV-33 1.6 4.0 0.8–7.3 4.3 5.3 1.5–9.1
HPV-56 1.6 3.2 0.3–6.2 1.0 3.2 0.2–6.2
HPV-59 1.6 2.4 0.0–5.0 3.2 3.2 0.2–6.2
HPV-51 0.8 1.6 0.0–3.7 2.1 3.2 0.2–6.2
HPV-52 — 0.8 0.0–2.3 2.1 4.2 0.8–7.7
HPV-35 0.8 0.8 0.0–2.3 3.2 3.2 0.2–6.2
HPV-68 1.6 1.6 0.0–3.7 — 1.0 0.0–2.8
HPV-39 — 1.6 0.0–3.7 1.0 1.0 0.0–2.8
HPV-82 — — — 1.0 1.0 0.0–2.8
HPV-73 — 0.8 0.0–2.3 — — —
Low risk
Any LR-HPV — 4.9 1.3–8.4% 1.0 3.2 0.2–6.2
HPV-44 — 3.2 0.3–6.2 1.0 1.0 0.0–2.8
HPV-42 — 0.8 0.0–2.3 — 2.2 0.0–4.5
HPV-72 — 0.8 0.0–2.3 — — —
HPV-61 — 0.8 0.0–2.3 — — —
Probable high risk
HPV-26 — 5.7 1.9–9.5 — 5.3 1.5–9.1
HPV-66 0.8 1.6 0.0–3.7 — — —
HPV-53 — 0.8 0.0–2.3 1.0 2.1 0.0–4.5
Undetermined risk∗
HPV-34 — 0.8 0.0–2.3 — 1.0 0.0–2.8
HPV-83 — 0.8 0.0–2.3 — — —
(b) Prevalence of multiple infections
HPV type Bogota Barranquilla
% 95%CI % 95%CI
High riskIHigh risk
HPVs 16-31 0.8 0.0–2.2 1.1 0.0–2.8
HPVs 16-others 0.8 0.0–2.2 1.1 0.0–2.8
HPVs 18-39 0.8 0.0–2.2 — —
HPVs 18-45 0.8 0.0–2.2 — —
HPVs 33-53 — — 1.1 0.0–2.8
HPVs 45-53 0.8 0.0–2.2 — —
HPVs 51-56 0.8 0.0–2.2 1.1 0.0–2.8
HPVs 58-68 — — 1.1 0.0–2.8
HPVs 73-31-33 0.8 0.0–2.2 — —
High risk/Probably high risk
HPVs 16-26 — — 3.2 0.2–6.2
HPVs 18-26 5.7 1.9–9.5 2.1 0.0–4.6
HPVs 52-66 0.8 0.0–2.3 — —Infectious Diseases in Obstetrics and Gynecology 5
(b) Continued.
HPV type Bogota Barranquilla
% 95%CI % 95%CI
High riskIUndetermined risk∗
HPVs 18-83 0.8 0.0–2.3 — —
HPVs 33-34 0.8 0.0–2.3 — —
HPVs 52-34 — — 1.1 0.0–2.8
High risk/Low risk
HPVs 16-42 — — 1.1 0.0–2.8
HPVs 18-44 0.8 0.0–2.3 — —
HPVs 45-42 0.8 0.0–2.3 — —
HPVs 56-others 0.8 0.0–2.3 1.1 0.0–2.8
HPVs 59-44 0.8 0.0–2.3 — —
HPVs 33-72 0.8 0.0–2.3 — —
HPVs 58-44-61 0.8 0.0–2.3 — —
Classiﬁaction based on 19. Prevalence as percentage of cases for single infections, all infections (single and multiple), and multiple infections.
∗HPV types without proper evaluation in case control studies but classiﬁed as low risk according to the phylogenetic origin.
HPV types varied among women depending upon age at
diagnosis of cervical cancer. For women under 50 the most
common types were HPV-16 (55.4%), HPV-45 (14.3%),
HPV-18 (10.1%), and HPV-31 (5.4%); for women 50-59,
the most common types were HPV-16 (55.3%), HPV-18
(21.8%), HPV-58 (8%), and HPV-56 (3.4%); for women
over 60, the most common types were HPV-16 (37.9%),
HPV-58 (11.9%), HPV-33 (10.7%), and HPV-31 (9.8%).
When considering age distribution for a given HPV type,
HPVs 16 and 18 distributed evenly across age groups; most
HPV-45 infections occurred before age 50 (82%, P = .02),
and less common types (HPV 58 and 33) occurred mostly
after age 50 and even over 60 (P>. 05) (Figure 2).
4. Discussion
Our study is the largest on the subject in Colombia and one
of the few published in Latin America. Previous information
from Colombia included 125 cases in two studies with no
ACC [20].
Several reports indicate that ACC has increased as a
result of successful cervical cancer screening programs;
however, the distribution of histological types in our report
is similar to other studies in the region [20], and there were
no diﬀerences among high-risk and low-middle-risk areas,
regardless of diﬀerences in performance of cytology-based
programs.
Our data show good sensitivity for the combined tech-
niques of HPV detection, with better performance than in
previous studies from Colombia, and similar to that from
other regional reports and from developed nations [20, 21].
HPV-DNA detection was carried out using GP5+/GP6+ L1
primers, RLB assays, and E7 type speciﬁc PCR, allowing for
98% HPV detection among β-globin positive samples, and
overall 99% HR-HPV detection among HPV positives. The
highdetectionratesassureavoidingunderestimationofHPV
prevalence particularly for HR-HPV where all cases reported
a speciﬁc type.
Table 3: HPV distribution according to histological characteristics.
HPV type Squamous cell carcinoma Adenocarcinoma
% C195% % C195%
HPV-16 51.5 43.4–59.6 46.8 25.4–68.3
HPV-18 10.8 3.8–17.7 32.9 10.9–54.9
HPV-45 9.0 4.7–13.3 — —
HPV-31 4.5 1.2–7.8 14.9 1.1–28.7
HPV-58 6.6 2.7–10.6 — —
HPV-33 4.5 1.2–7.8 — —
HPV-56 2.8 0.2–5.7 2.7 1.8–7.2
HPV-59 2.8 0.2–5.7 2.7 1.8–7.2
HPV-52 1.0 0.0–2.0 — —
HPV-35 1.7 0.1–3.4 — —
HPV-44 0.3 0.2–0.9 — —
Other HR 4.5 — — —
Estimations are based on 208 cases (SCC 185, ADC 23).
Single infections assumed after distribution of multiple infections.
The largest previous Colombian survey included 87 cases
with a restricted 72.4% HPV detection rate, in which only
ﬁve HR-HPV types were analyzed using MY09/11 (exclusive
of HPV-45 which played an important role in our study)
[20]. A study that compared GP5+/GP6+ and MY09/11
showed similar global HPV detection sensitivity, but lower
sensitivity detecting multiple infections with GP5+/GP6+
[22]; however, the diﬀerences between methods were not
assessed and there were problems in primer design since
the PCR product in the study did not include all regions
corresponding to type-speciﬁc oligonucleotide probes for
GP5+/GP6+.
In our study, type speciﬁc prevalence was similar to that
foundinaggregativeanalysis,whereHPVs16/18arethemost
frequent [21]. As in those reports, our data likewise showed
lower HPV 16/18 participation (63.1%) than observed
in developed countries and in worldwide estimates [21].6 Infectious Diseases in Obstetrics and Gynecology
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Figure 1: Cervical cancer cases and related HPV infections. (a) Only HPV types counted as single infections are included. Every cervical
cancer case is attributable to solely one HPV type. Cases with multiple HR-HPV infections were proportionally distributed as described in
the methods section. (b) Only HR-HPV types are included. HR-LR HPV coinfections (30.6% of multiple infections) were assumed as single
infections for the carcinogenic process. ∗LR-HPV type with single infections as described in Table 2. ∗∗HR-HPV types observed exclusively
in multiple infections.
Other
HR-HPV
HPV-33
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Figure 2: Distribution of HPV types over and under age 50. Each
bar represents 100% of cases for each HPV type. HR-HPV types
countedinlessthan10casesweregroupedasotherHR-HPV.Single
infections assumed after distribution of multiple infections.
Our results reproduce ﬁndings indicating that the role
of HPV-18 in higher-risk areas might be slightly lower;
consequently, the participation of rare HR-HPV becomes
more relevant, such as in the case of Barranquilla (Table 2).
Nevertheless, there were no signiﬁcant diﬀerences between
the two Colombian cities due to the lower prevalence found
in Barranquilla.
As regards ADC, HPV-18 was signiﬁcantly more preva-
lent than in SCC (34.3%) (Table 3), and these results
were coincident with previous evidence [21]. However,
less common HR-HPV types, such as HPV-31, were more
prevalent in ADC in our study (particularly in the high risk
city), and HPV-45 was not attributed to any ADC case after
distribution of multiple infections.Infectious Diseases in Obstetrics and Gynecology 7
When we turn our attention to the participation of
multiple HPV types in a single case, we ﬁnd out that
it correlates with population risk and is coherent with
the higher prevalence of multiple infections in developing
countries: Africa 12.4%, South/Central America 11%, Asia
7.8%, Europe 6.2%, and North America 5.1% [20].
The existence of multiple infections increases the possi-
bility of HPV replacement following vaccination and should
be taken into account as a potential decliner of vaccine
impact over time, mainly in developing nations where
population risk and number of HPV types are higher. This
issue is independent from that of assigning a speciﬁc HPV
type to a speciﬁc lesion which is the main concern of vaccine
eﬃcacy in clinical trials [23].
Multiple infections have been dealt with diﬀerently in
several studies: most estimates assume unique multiple-
infection several times for diﬀerent HPV types, resulting in
overestimation of type speciﬁc prevalence [9, 20]. In other
cases, multiple infections have been assigned in proportional
f r a c t i o n st oe a c hg e n o t y p eb u tc o u n t e do n l yo n c ea si n
our study [17]. In order to ensure that specimen analysis
met the highest international standards, we adhered to
a strict protocol that greatly reduced the possibility of
contamination. In our study, the percentage of multiple
HR-HPV infections was higher than in reports from Africa
(16.6% versus 12.4%) but occupied a mean position when
compared to data from Latin American countries which
rangesfrom4.3%inBrazilto33.3%inMexico[20,24].Only
3 out of 8 regional reports show multiple infections under
10%.
Even so, existing information on multiple infections
lacks consistency making it diﬃcult to use for vaccine
assessment: diﬀerences in PCR technique sensitivity are
greater for detecting multiple infections, several reports
do not present data on multiple infections, and studies
reporting data on the topic use diﬀerent structures. Thus,
detailed information on multiple HR-HPV infections ought
to be more relevant for developing countries, and this is
particularly important for HPV-18. The 47% of multiple
infections among HPV-18 in our study (Figure 1) is higher
than the percentage in a worldwide metanalysis (20%)
but similar to reports from Peru (56%) and lower than
reports from Paraguay (90%) [17, 25, 26]. However, most
HPV-18 multiple infections in our study occurred with a
probable high-risk type (HPV-26) indicating a low chance
of replacement.
In Colombia, as in other Latin American countries,
a double peak of HPV prevalence and incidence among
women with normal cytology has been described: after an
initial high HR-HPV incidence in young women, there is a
decline that goes up again around menopause [21]. In our
report, type-speciﬁc HPV prevalence among women under
age 50 was diﬀerent than prevalence among postmenopausal
women with invasive cancer; likewise, prevalence after ten
years since the second incidence peak was also diﬀerent
(prevalence over age 60).
Diﬀerential age-speciﬁc type prevalence might have
diﬀerent eﬀects on global vaccine impact according to
age-speciﬁc cervical cancer incidence. Thus, in Colombia
less than 50% of invasive cancer occurs under age 50
which would imply a slightly lower impact of HPV 16/18
vaccines when the estimations are based on age-speciﬁc
HPV prevalence (Table 4). On the contrary, in a given
population with a larger percentage of cases under age 50,
the estimated impact based on age-speciﬁc prevalence would
be higher than impact based on global estimates if applying
the observed age-speciﬁc prevalence in our study [6]. A large
percentage of cases under age 50 could be seen in high-risk
and low-risk populations, in this latter case due to the high
percentage of ADC as a result of eﬀective cervical cancer
screening.
Age-speciﬁc prevalence reveals an important role for
HPV types other than HPV 16/18. The higher percentage
of HPV-45 in young women (Figure 2)h a sb e e np r e v i -
ously described in worldwide analyses [17]. As a result,
a vaccine including HPV-45 would have greater eﬀect on
populations with a higher percentage of under age 50
cases (Table 4), but, due to the higher participation of HR-
HPV types other than 16/18 among high-risk populations,
this eﬀect would be more likely to occur in developing
countries (especially Latin America) than in developed
ones.
In summary, we obtained similar results as those found
in previous Latin American surveys, but we observed two
relevant factors with the potential to inﬂuence the impact
of HPV vaccines. Our data ﬁndings on multiple infections
and age-speciﬁc prevalence are consistent with the scarce
data on these topics and have further brought to light the
role of HPVs other than 16/18. If the impacts of the HPV-18
vaccination were to diminish due to replacement in multiple
infections, cross-protection for HPV-45 would be an asset
[27]. In addition, a protective eﬀect against HPV-45 would
ensure greater impact of current vaccines given the age-
speciﬁc prevalence (up to 14% percent gained over global
estimates for HPV 16/18 with an age-speciﬁc incidence as in
Connecticut—Table 4).
Although if no cross-protection against HPV-45 could be
fully demonstrated, our data highlight the necessity for well-
designed future generation vaccines. Immune interference
when adding HPV types might have negative eﬀects on
vaccineeﬃcacyordurationofprotection[27,28].Therefore,
if a global vaccine with over 90% protection were not
possible, a good deﬁnition of target populations based on
HPV epidemiology would be required to obtain the greatest
impactwiththelowestnumberofHPVtypes(developedand
developingcountries,youngandmiddle-agewomen,regions
of the world, etc.).
Our results challenge the discussion on HPV vaccine
impact in developing nations where factors such as lower
vaccine coverage and screening compliance will decrease
population eﬀectofvaccination. Hence,wewouldencourage
the use of our data for assessing vaccine cost-eﬀectiveness in
Colombia and other Latin American countries. Yet, reports
on multiple infections must attain a more standardized
structure in future studies and ﬁndings on single LR-HPV
infections need to be better understood, where diﬀerences
between phylogenetic and epidemiologic classiﬁcations may
play a part.8 Infectious Diseases in Obstetrics and Gynecology
Table 4: Impact of HPV vaccines according to age speciﬁc HPV prevalence.
(a) Cervical cancer incident cases
Country Group of age Total∗
<50 50–59 ≥60
Colombia, Cali 489 217 339 1045
Uganda, Kyadondo County 313 69 70 452
USA, Connecticut 382 52 46 480
(b) Expected incident cases and estimated impact of vaccination
Case <50 50–59 ≥60 Impact based on
global estimates
Impact based on
age-speciﬁc
estimates
HPV 16,18
Attributable cases (%) 65.5 77.1 46.3 63.2 —
Colombia, Cali 169 50 182 63.2 61.7
Uganda, Kyadondo County 108 16 38 63.2 64.3
USA, Connecticut 132 12 25 63.2 64.9
HPV 16,18,45
Attributable cases (%) 79.8 79.4 48.6 71.4 —
Colombia, Cali 99 45 174 71.4 69.6
Uganda, Kyadondo County 63 14 36 71.4 74.9
USA, Connecticut 77 11 24 71.4 76.8
HPV 16,18,45,31
Attributable cases (%) 85.2 80.6 58.4 76.8 —
Colombia, Cali 72 42 141 76.8 75.6
Uganda, Kyadondo County 46 13 29 76.8 80.3
USA, Connecticut 57 10 19 76.8 82.1
HPV 16,18,45,58
Attributable cases (%) 81.6 87.4 60.6 77.3 —
Colombia, Cali 90 27 134 77.3 76.0
Uganda, Kyadondo County 58 9 28 77.3 79.2
USA, Connecticut 70 7 18 77.3 80.2
Incident cases in (a) based on 28. Attributable cases based on study results. Numbers for each country in (b) correspond to the expected number of cases
given the percentage of attributable cases. The impact based on global estimates was obtained from cumulative percentages in Figure 1(a). The impact based
on age-speciﬁc estimates corresponds to the reduction in number of cases as percentage of the initial number of cases, obtained from the summatory of
expected cases in age groups (<50, 50–59, ≥60). Single infections assumed after distribution of multiple infections.
∗Total cases do not include unknown age.
Novelty
This is the largest study on the topic in Colombia and Latin
America. With an excellent PCR technique sensitivity for
HPV detection, key issues previously narrowly analyzed such
asmultipleinfections,age-speciﬁcprevalence,andtheroleof
HPVs other than 16/18, are demonstrated as relevant factors
inﬂuencing HPV vaccine impact among high-risk cervical
cancer populations (developing countries). The data are
useful to improve cost-eﬀectiveness analyses and to discuss
second generation HPV vaccines.
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